This page shows the latest paliperidone palmitate news and features for those working in and with pharma, biotech and healthcare.
Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that
The drug is one of several new antipsychotic agents expected to drive growth in the schizophrenia market in the coming years, along with Johnson &Johnson's three-monthly paliperidone palmitate depot,
The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Before patients can be started on the drug they must first be taking Janssen's Invega Sustenna, a one-month form of paliperidone palmitate,
The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as
Added to that, the pharma company has just stopped a trial of its three-monthly formulation of Risperdal (risperidone) follow-up paliperidone palmitate on positive results, setting up a filing later ... Three-monthly paliperidone. Meanwhile, J&J could
The company said the sales increase was also helped by new pharmaceutical product introductions, including its depot antipsychotic Invega Sustenna/Xeplion (paliperidone palmitate), which grew 76 per cent to $284m in
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...